Effect of Amlodipine on the Lipid Profile of Newly Diagnosed Hypertensive Patients

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05467384

Enrollment

Registered

2022-07-20

Start date

2016-03-01

Completion date

2017-06-30

Last updated

2022-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholesterol Deposition, Hypercholesterolemia, Hypertension

Keywords

Hypercholesterolemia, Hypertension

Brief summary

In this study, Amlodipine has been used to study its effects in newly diagnosed hypertensive patients.

Detailed description

The incidence of hypertension is on the rise in developing countries like Pakistan. Different medications are used to decrease blood pressure with Amlodipine as one of the first-line drugs. It was proposed that due to interaction with calcium and thus luminal cholecystokinin releasing factor; Amlodipine might increase the cholesterol level and thus cause dyslipidemia. Objective: In this regard, this study was conducted to look into the effects of Amlodipine in newly diagnosed cases of hypertension that had received no medication previously. Methodology: Experimental study with a healthy control group with the sample size calculated out to be 80, comprising of an equal number of enrolment into case and control groups.

Interventions

DRUGAmlodipine

5mg/day in two divided doses

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Caregiver)

Intervention model description

Case with healthy control

Eligibility

Sex/Gender

ALL

Age

20 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

for cases. 1\) Newly diagnosed mild to moderate hypertensive. (2) Non-obese individuals. 3) Must not have received antihypertensive treatment previously. 4) Has elevated serum cholesterol levels.

Exclusion criteria

for cases 1\) Any other major illness. Inclusion criteria for controls 1. Normal lipid profile. 2. Normotensive (BP \< 140/90mmHg).

Design outcomes

Primary

Measure	Time frame	Description
Measurement of Blood Glucose Concentration	Four Months	Measured as per protocols provided by the kit manufacturer.
Measurement of Total Plasma Cholesterol Concentration	Four Months	Measured as per protocols provided by the kit manufacturer.
Measurement of Plasma Triglyceride Concentration	Four Months	Measured as per protocols provided by the kit manufacturer.
Measurement of Plasma High Density Lipoproteins Concentration	Four Months	Measured as per protocols provided by the kit manufacturer.
Measurement of Plasma Low Density Lipoproteins Concentration	Four Months	Measured as per protocols provided by the kit manufacturer.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026